Although some of the companies are multi-divisional, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique because it analyses the individual cost components of each company over time and generates pharma industry weighted averages, allowing peer and industry comparisons to be made. It also generates individual company and industry-wide underlying operating profit (EBIT), both pre-R&D and post R&D.
Historically, data from over 100 companies has been accumulated, but industry consolidation means that just 40 are included currently, which command an estimated 76% of the global drug industry. The main exceptions are the Chinese companies where insufficient data are available on a consistent basis.
Current companies included in dataset:
Click here to find out more:
https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
Special Working Group Committed to Strengthening Chinese Investment in Preah Sihanouk Province HONG KONG SAR…
HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - On the evening…
HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - Paul Chan, Financial…
Enticing promotions to thank customers for their support HONG KONG SAR - Media OutReach Newswire…
HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 1 November 2024 - Ho…
HONG KONG SAR – Media OutReach Newswire - 1 November 2024 – Lionrock Property is…